<DOC>
	<DOCNO>NCT01348087</DOCNO>
	<brief_summary>The purpose study generate long-term safety , tolerability efficacy data AFQ056 eligible adult patient FXS participate CAFQ056A2212 ( NCT01253629 ) .study patient participate previous proof-of-concept study CAFQ056A2204 ( NCT00718341 ) .</brief_summary>
	<brief_title>Long-term , Safety , Tolerability Efficacy Study AFQ056 Adult Patients With Fragile X Syndrome</brief_title>
	<detailed_description>A 148 patient enrol treatment extension trial conduct least 3 year . This extension trial terminate decision terminate AFQ056 development program . The decision base result two randomized , double blind , placebo control phase IIb trial adult adolescent FXS patient ( CAFQ056A2212 CAFQ056B2214respectivly ) , fail demonstrate efficacy FXS population . As extension trial terminate , primary objective safety represent .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Inclusion criterion Group 1 patient Had complete CAFQ056A2212 study another study AFQ056 include adult FXS patient within one week enrollment openlabel study . Females childbearing potential follow protocol requirement respect contraception . Have caregiver caregiver spend , average , least six hour per day patient , willing capable supervising treatment , provide input efficacy safety assessment , accompany patient study visit . Group 2 : Had : Completed Study CAFQ056A2204 . Completed Study CAFQ056A2212 another study AFQ056 include adult patient FXS enrollment current study delay week . Discontinued prematurely Study CAFQ056A2212 another study AFQ056 include adult patient FXS due intolerability dosage patient 's assigned treatment group . Females childbearing potential follow protocol requirement respect contraception . Have caregiver caregiver spend , average , least six hour per day patient , willing capable supervising treatment , provide input efficacy safety assessment , accompany patient study visit Exclusion criterion Any advance , severe unstable disease History severe self injurious behavior History uncontrolled seizure disorder resistant therapy within past 2 year ( Patients clinically stable anticonvulsant therapy past 2 year exclude ) History clinically significant allergy require hospitalization non inhale corticosteroid therapy ( asthma , anaphylaxis , etc . ) Using ( use within 6 week baseline ) concomitant medication potent inhibitor inducer CYP3A4 Using glutamatergic agent ( riluzole , memantine , etc . ) lithium , digoxin , warfarin within 6 week baseline Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>Martin-Bell Syndrome</keyword>
	<keyword>Genetic Diseases</keyword>
	<keyword>X-Linked</keyword>
	<keyword>Escalante 's syndrome</keyword>
</DOC>